65,437 trials
Carcinoma, Renal Cell
Primary: Number of Participants With Preference for Pazopanib Versus Sunitinib as Assessed by the Patient Preference Questionnaire (PPQ) — 19; 6; 37; 43 participants — p=<0.001
Pulmonary Arterial Hypertension
Primary: Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) - Number of Patients With…
Hepatitis B Virus · HBV
Primary: Overall Study: Number of Participants With Death As Outcome, Any Adverse Event (AE), Grade 3-4 AEs, Serious Adverse Events (SAEs), and Discontinuations Due to AEs — 18…
Hernia
Primary: Number of Subjects With Hernia Recurrence Post Repair With an AlloMax Surgical Graft — 17 participants
Oral Mucositis
Primary: Ratio to Baseline of Epithelial Cell Proliferation as Assessed by Ki67 Staining of Buccal Mucosal Tissue. — 0.267; 0.414 ratio
Benign Prostatic Hyperplasia (BPH)
Primary: Change of IPSS at the 6th Week Compared With Baseline(Intention to Treat) — 7.26; 2.34 units on a scale — p=< 0.01
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change on Ocular Surface Disease Index (OSDI)
Leukemia
Primary: Continuous Complete Remission at 1 Year — 21 participants
Pulmonary Arterial Hypertension
Primary: Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 2 ng/kg/Min — 98.0; 83.1 (pg/ml)/(ng/kg/min)
Tinnitus
Primary: Brain Speed Test — -0.09 z-score
Myopia
Primary: Visual Acuity — -0.10; -0.10; 0.17; 0.18 logMAR scale
Breast Cancer
Primary: Progression-free Survival (PFS) Rate: Percentage of Participants With PFS — 59.6; 90.5; 30.8; 81.0 percentage of participants
Primary Immunodeficiency Diseases (PID)
Primary: Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part…
Ovarian Cancer
Primary: Twelve-month Progression-free Survival (PFS) Rate in Participants — 65.7 percentage of participants
Heart Failure · Pacing · Bradycardia
Primary: Model 4965 Complication Free Rate — 98.8 Model 4965 complication free rate